Advanced triple quadrupole technology for improved performance and ease of use - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advanced triple quadrupole technology for improved performance and ease of use
Advanced triple quadrupole technology for improved performance and ease of use.


Pharmaceutical Technology
Volume 38, Issue 2, pp. 30-33

In all mass spectrometry applications, increased resolution, mass accuracy, and speed are sought. While the necessary resolution and sensitivity can be achieved by pushing an older instrument to its limits, the consequences of doing so are often more challenging method development and sample analysis and more frequent maintenance resulting from larger injection volumes, explains Patrick Bennett, marketing director for pharmaceuticals and biopharmaceuticals at Thermo Fisher Scientific (TFS).

Two new instruments from TFS address the need for increased sensitivity for small-molecule analysis. “The TSQ Endura triple-stage quadrupole mass spectrometer has a new ion source design and interface and an ion beam blocker that prevents neutral ions from contaminating components, thus improving robustness and dramatically increasing uptime, making the system ideal for workhorse applications requiring trace-level quantitation,” Bennett observes.

The TSQ Quantiva triple-stage quadrupole mass spectrometer has the same new source and simplified maintenance design as the TSQ Endura, plus active ion management (AIM) to optimize ion creation and transmission from the source to the detector, which provides sensitivity to the attogram level. According to Bennett, the increased scanning speed of the new design also makes it possible to screen several hundreds of compounds in a single analysis.

TFS also made the user interface for each system simple with click-and-drag operations, and included new software with templates for rapid method development and data acquisition, programs designed to assist molecule identification, and mass spectral databases for the identification and structural elucidation of unknowns. “Our goal was not only to develop highly sophisticated systems that provide the resolution, speed, and mass accuracy needed for various pharmaceutical industry analyses, but also to make them easy to use by both those with extensive training and those that are new to mass spectrometry,” states Bennett. increasing numbers of complex and innovative products and suppliers  and discuss ways the pharmaceutical industry can collaborate to assure the delivery of high-quality medicines in an ever-increasing complex and global marketplace.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here